Studying the Serum as Well as Serous Level of IL-17 and IL-23 in Patients with Serous Otitis Media

  • Ahmad Yeghaneh Moghaddam Department of ENT, Kashan University of Medical Sciences, Kashan, Iran
  • Rezvan Talaei Autoimmune Research Center, Kashan University of Medical Sciences, Kashan, Iran
  • Hassan Nikoueinejad Department of Immunology, Baqiyatallah University of Medical Sciences, Tehran, Iran AND Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
  • Hossein Akbari Trauma Research center, Kashan University of Medical Sciences, Kashan, Iran
Keywords: Interleukin 17, Interleukin 23, Otitis media with effusion


Serous otitis media with effusion (OME) is a middle ear inflammatory response to allergens and microbes which stimulate leukocytes to produce different inflammatory mediators after obstruction of Eustachian tube. Here, we investigated the levels of these mediators, IL-17 and IL-23, in serum and middle ear fluids of children with OME. 75 patients with otitis media and 75 age and sex-matched healthy controls were enrolled in this study. IL-17 and IL-23 levels in serous secretion of the patients and their serum levels were measured in both groups by ELISA. Serum IL-17 levels were significantly higher in the patients than controls (p=0.001). There was no significant difference between serum IL-23 levels in patients and controls. Patients’ serous levels of both cytokines of IL-17 and IL-23 were higher than those in serum according to different parameters of sex, age, and duration of the disease. This study shows an elevated presence of IL-17 and IL-23, as pro inflammatory cytokines, in OME. These finding may represent the contribution of such cytokines in the pathogenesis of OME. Blocking such molecules may yield new non-surgical therapeutics. 


1. Mittal R, Robalino G, Gerring R, Chan B, Yan D, Grati Mh, et al. Immunity Genes and Susceptibility to Otitis Media: A Comprehensive Review. Journal of Genetics and Genomics. 2014;41(11):567-81.2. Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nature reviews Immunology. 2014;14(9):585-600.3. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. The Journal of experimental medicine. 2005;201(2):233-40.4. Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation. The Journal of clinical investigation 116(5):1218-22.5. Infante-Duarte C, Horton HF, Byrne MC, Kamradt T. Microbial lipopeptides induce the production of IL-17 in Th cells. Journal of immunology (Baltimore, Md : 1950). 2000;165(11):6107-15.6. Qu N, Xu M, Mizoguchi I, Furusawa J, Kaneko K, Watanabe K, et al. Pivotal roles of T-helper 17-related cytokines, IL-17, IL-22, and IL-23, in inflammatory diseases. Clinical & developmental immunology. 2013;2013:968549.7. Jin W, Dong C. IL-17 cytokines in immunity and inflammation. Emerging microbes & infections. 2013;2(9):e60.8. Roussel L, Houle F, Chan C, Yao Y, Berube J, Olivenstein R, et al. IL-17 promotes p38 MAPK-dependent endothelial activation enhancing neutrophil recruitment to sites of inflammation. Journal of immunology (Baltimore, Md : 1950). 2010;184(8):4531-7.9. Louten J, Boniface K, de Waal Malefyt R. Development and function of TH17 cells in health and disease. The Journal of allergy and clinical immunology. 2009;123(5):1004-11.10. Du C, Liu C, Kang J, Zhao G, Ye Z, Huang S, et al. MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nature immunology. 2009;10(12):1252-9.11. van Beelen AJ, Teunissen MB, Kapsenberg ML, de Jong EC. Interleukin-17 in inflammatory skin disorders. Current opinion in allergy and clinical immunology. 2007;7(5):374-81.12. Basoglu MS, Eren E, Aslan H, Kolatan HE, Ozbay C, Inan S, et al. Increased expression of VEGF, iNOS, IL-1beta, and IL-17 in a rabbit model of gastric content-induced middle ear inflammation. International journal of pediatric otorhinolaryngology. 2012;76(1):64-9.13. Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003;52(1):65-70.14. Wong CK, Lit LC, Tam LS, Li EK, Wong PT, Lam CW. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clinical immunology (Orlando, Fla). 2008;127(3):385-93.15. Wang W, Zhou A, Zhang X, Xiang Y, Huang Y, Wang L, et al. Interleukin 17A promotes pneumococcal clearance by recruiting neutrophils and inducing apoptosis through a p38 mitogen-activated protein kinase-dependent mechanism in acute otitis media. Infection and immunity. 2014;82(6):2368-77.16. Ye X, Zhang L, Wang H, Chen Y, Zhang W, Zhu R, et al. The role of IL-23/Th17 pathway in patients with primary immune thrombocytopenia. PloS one. 2015;10(1):e0117704.17. Jiang Z, Hennein L, Tao Y, Tao L. Interleukin-23 Receptor Gene Polymorphism May Enhance Expression of the IL-23 Receptor, IL-17, TNF-alpha and IL-6 in Behcet's Disease. PloS one. 2015;10(7):e0134632.18. McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382(9894):780-9.19. Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Secukinumab in plaque psoriasis--results of two phase 3 trials. The New England journal of medicine. 2014;371(4):326-38.20. Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. The New England journal of medicine. 2012;366(13):1190-9.21. Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. The New England journal of medicine. 2012;366(13):1181-9.22. Sofen H, Smith S, Matheson RT, Leonardi CL, Calderon C, Brodmerkel C, et al. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. The Journal of allergy and clinical immunology. 2014;133(4):1032-40.

How to Cite
Yeghaneh Moghaddam A, Talaei R, Nikoueinejad H, Akbari H. Studying the Serum as Well as Serous Level of IL-17 and IL-23 in Patients with Serous Otitis Media. ijaai. 16(6):520-4.
Original Article(s)